Semaglutide 10mg

Semaglutide | 10mg

The compound that changed the conversation around metabolic health. Semaglutide is a long-acting GLP-1 receptor agonist developed by Novo Nordisk and one of the most extensively studied compounds in modern clinical research — backed by the landmark STEP and SELECT trial programmes involving tens of thousands of participants across multiple continents.

What Research Suggests Semaglutide May Support:

Significant & Sustained Weight Reduction — STEP trial data demonstrated average body weight reductions of 14.9% to 17.4% over 68 weeks, with the majority of participants achieving reductions of 10% or more — results that established semaglutide as the benchmark against which subsequent metabolic compounds are measured.

Blood Sugar & Glycaemic Control — Research across the SUSTAIN and PIONEER programmes consistently demonstrated meaningful reductions in HbA1c and fasting plasma glucose, with benefits observed regardless of age, duration of diabetes, or dose — establishing semaglutide as a leading compound in type 2 diabetes management research.

Cardiovascular Risk Reduction — In the landmark SELECT trial involving over 17,600 participants, semaglutide produced a 20% reduction in major adverse cardiovascular events including heart attack and stroke, leading researchers to propose it be reclassified as a disease-modifying treatment rather than simply a weight loss compound.

Appetite Regulation & Satiety — By activating GLP-1 receptors in the hypothalamus and gut, semaglutide slows gastric emptying and promotes sustained satiety — supporting meaningful and consistent reductions in caloric intake across the full duration of research protocols.

Cardiometabolic Health — Research points to broad improvements across multiple cardiometabolic markers including systolic blood pressure, waist circumference, triglycerides, LDL cholesterol, and high-sensitivity C-reactive protein — reflecting a cardiovascular benefit profile that extends well beyond weight reduction alone.

Diabetes Prevention — Research has demonstrated that semaglutide dramatically reduces the progression from prediabetes to type 2 diabetes, with SELECT trial data showing new-onset diabetes occurring in just 3.5% of semaglutide participants compared to 12% in the placebo group over the study period.